ALSO NOTED: SGX prices IPO; Syngenta invests in Avidex; GSK in talks on Cervarix; and much more...

> SGX has priced its planned IPO of 4 million shares at $11 to $13 per share. Report

> Switzerland's Syngenta has made a £5 million investment in UK biotech Avidex. Syngenta gained a minority equity stake in the company. Release

> The UK's GlaxoSmithKline says it is still talking with the FDA about its Cervarix cervical cancer vaccine but hopes to quickly outline its plans to submit the treatment for federal approval. Report

> Pain Therapeutics has received a $150 million up front payment as part of its collaboration agreement with King Pharmaceuticals to collaborate on a new version of Oxycontin that will be harder to abuse. Report

> The FDA has approved Schering's Climara Pro hormone patch for bone fragility after menopause. Report

> Santhera has announced the successful management buyout of its Graffinity technology unit. Release

> Sangamo BioSciences has expanded its research partnership with Pfizer in the field of enhanced protein production. Release

> Xencor and Roche have extended their research collaboration. Release

And Finally… Unlike a lot of old wives' tales, the one about fish being food for the brain turns out to be true. Article

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.